Politics

HC Wainwrights Raghuram Selvaraju says Tiziana Life Sciences PLC worth US$25 a share; Alzheimers represents “massive market”

Tiziana Life Science PLC (LON:TILS; NASDAQ:TLSA) is worth around 300% more than the current share price based on just two of its potential pipeline developments, according to HC Wainwright.

The broker reiterated its US$25 price target and 'buy' rating for the Nasdaq-listed ADS following the biotech's recent updates on two projects: foralumab and StemPrintER.

This target, though excludes any contribution in future from foralumab beyond Crohn's disease or milciclib in cancers beyond HCC (liver); or indeed anything from StemPrintER or TZLS-501 (coronavirus), said the broker.

“Positive clinical data with foralumab for indications representing massive markets like AD (Alzheimers) and MS (multiple sclerosis) could thus constitute a considerable upside to our assumptions,” added analyst Raghuram Selvaraju.

Earlier this week, Tiziana reported that Howard Weiner, the chairman of its scientific advisory board, had received a grant from the NIH to investigate foralumab, its nasally delivered anti-CD3 monoclonal antibody (mAb), as a possible Alzheimer's treatment.

The grant followed a demonstration by Weiner that unexpectedly found that the nasally delivered anti-CD3 modulated brain microglia in animal models.

Activated microglia have been shown in studies to essentially 'erase' memories in mice, said Selvaraju.

Tiziana has a worldwide exclusive licence for nasal administration of anti-CD3 mAbs for the treatment of neurodegenerative diseases including Alzheimers, noted the analyst, from Brigham and Womens Hospital, Harvard Medical School, Boston.

A breakthrough in Alzheimers is being urgently sought.

The developments at Tiziana come as Biogen Inc (NASDAQ:BIIB) is readying to launch aducanumab, which, when it goes live will be the only commercially available product developed specifically to treat the disease.

Peak sales are tipped to hit US$10bn, and, with pent up demand worldwide, revenues from the Biogen breakthrough are expected to rise rapidly, analysts said.

Phase I trials of foralumab have focused on its use aRead More – Source

[contf] [contfnew]

Proactiveinvestors

[contfnewc] [contfnewc]

Related Articles

Back to top button